Bank of Montreal
CLDX icon

Bank of Montreal’s Celldex Therapeutics CLDX Stock Holding History

Bank of Montreal’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$387K Sell
10,395
-2,600
-20% -$84K ﹤0.01% 2617
2026
Q1 		$412K Buy
+12,995
New +$354K ﹤0.01% 2485
2025
Q2 		– Sell
-19,607
Closed -$356K – 3540
2025
Q1 		$356K Buy
+19,607
New +$438K ﹤0.01% 2405
2023
Q2 		– Sell
-26,980
Closed -$1.12M – 4007
2023
Q1 		$1.12M Sell
26,980
-1,968
-7% -$84.9K ﹤0.01% 1978
2022
Q4 		$1.32M Buy
+28,948
New +$1.03M ﹤0.01% 2020
2021
Q2 		– Sell
-60
Closed -$1K – 3887
2021
Q1 		$1K Hold
60
– – ﹤0.01% 4976
2020
Q4 		$1K Hold
60
– – ﹤0.01% 4864
2020
Q3 		$1K Hold
60
– – ﹤0.01% 4687
2020
Q2 		$1K Hold
60
– – ﹤0.01% 4551
2020
Q1 		$0 Hold
60
– – ﹤0.01% 4183
2019
Q4 		$0 Buy
+60
New +$139 ﹤0.01% 4862
2018
Q2 		– Sell
-333
Closed -$12K – 4726
2018
Q1 		$12K Hold
333
– – ﹤0.01% 3697
2017
Q4 		$14K Buy
+333
New +$14.3K ﹤0.01% 3683
2017
Q2 		– Sell
-3,256
Closed -$176K – 4149
2017
Q1 		$176K Hold
3,256
– – ﹤0.01% 2542
2016
Q4 		$186K Buy
3,256
+3,206
+6,412% +$182K ﹤0.01% 2524
2016
Q3 		$3K Sell
50
-2,809
-98% -$175K ﹤0.01% 3790
2016
Q2 		$188K Buy
2,859
+2,791
+4,104% +$177K ﹤0.01% 2500
2016
Q1 		$4K Sell
68
-6
-8% -$675 ﹤0.01% 3840
2015
Q4 		$17K Buy
74
+6
+9% +$1.31K ﹤0.01% 3444
2015
Q3 		$11K Sell
68
-3,335
-98% -$944K ﹤0.01% 3435
2015
Q2 		$1.29M Buy
3,403
+2,368
+229% +$940K ﹤0.01% 1558
2015
Q1 		$433K Sell
1,035
-556
-35% -$199K ﹤0.01% 2022
2014
Q4 		$436K Buy
1,591
+4
+0.3% +$994 ﹤0.01% 2130
2014
Q3 		$309K Sell
1,587
-651
-29% -$142K ﹤0.01% 2323
2014
Q2 		$548K Buy
+2,238
New +$505K ﹤0.01% 2032

Other funds holding CLDX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
LGM
Logos Global Management San Francisco, California $2.32B AUM 536.01% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Bank of Montreal's CLDX Position: Q2 2026 in Review

Bank of Montreal reduced its Celldex Therapeutics (CLDX) stake by 20% in Q2 2026, selling an estimated $84K and leaving 10,395 shares worth $387K. The position accounts for ﹤0.01% of the portfolio, ranked #2617.

Bank of Montreal first reported a position in CLDX in Q2 2014 and has held it in 25 quarters since. The position peaked at $1.32M in Q4 2022. 253 funds tracked by Wall St. Rank hold CLDX as of Q2 2026.

  • Bank of Montreal held 10,395 shares of Celldex Therapeutics worth $387K as of Q2 2026.
  • Bank of Montreal sold 2,600 Celldex Therapeutics shares in Q2 2026, an estimated $84K.
  • Celldex Therapeutics made up ﹤0.01% of Bank of Montreal's portfolio in Q2 2026, its #2617 holding.
  • Bank of Montreal first reported a position in Celldex Therapeutics in Q2 2014 and has held it in 25 quarters since.
  • Bank of Montreal's Celldex Therapeutics position peaked at $1.32M in Q4 2022.
  • 253 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q2 2026.

Based on Bank of Montreal's 13F filing for Q2 2026, filed 12 Aug 2026.